Clermont Ferrand cedex 01, France Clinical Trials

A listing of Clermont Ferrand cedex 01, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 100 clinical trials
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.

Investigator Site 55
 (121.2 away) Contact site
  • 28 views
  • 13 Jun, 2021
  • +238 other locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer

CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with Subcutaneous anti-PD-1 Treatment Phase 3 Design with 3 study Arms (A, B and C). Arms A and B consists of two study drugs, PF-06801591 plus BCG. Arm C consists of one study drug, BCG. The study is designed …

Polyclinique de Limoges Site Chenieux
 (87.6 away) Contact site
  • 10 views
  • 09 Jun, 2021
  • +207 other locations
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

epidermal growth factor receptor
epidermal growth factor
growth factor
cancer chemotherapy
lung carcinoma
Novartis Investigative Site
 (1.4 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +42 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

aubagio
evobrutinib
teriflunomide
Research Site 458
 (87.7 away) Contact site
  • 0 views
  • 19 Jun, 2021
  • +244 other locations
Balloon to Induce Labor in Generous Women.

The rate of obesity increases continuously in France as in many developing countries.The risk of cesarean delivery is increased in obese compared to normal-weight women and postpartum complications as infections, thromboembolic events and related maternal death, are more common among obese women who deliver by cesarean than both normal-weight women …

CHU Clermont-Ferrand
 (1.6 away) Contact site
  • 0 views
  • 26 Jan, 2021
  • +17 other locations
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance …

aubagio
teriflunomide
contraceptive use
pregnancy test urine
hmr1726
Investigational Site Number 2500005
 (2.1 away) Contact site
  • 10 views
  • 23 Jun, 2021
  • +121 other locations
Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

This study will assess the safety, tolerability, and efficacy of Atogepant 60 mg compared with placebo in episodic migraines in participants who previously failed 2 to 4 classes of oral prophylactic treatments.

CHU Gabriel Montpied
 (1.6 away) Contact site
  • 0 views
  • 12 Jun, 2021
  • +134 other locations
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days …

APHM H pital de la Timone
 (204.2 away) Contact site
  • 0 views
  • 23 Jun, 2021
  • +76 other locations
Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr

Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World. For the patients presenting a NSCLC stage IV, the median of survival is about 15 months today. The chemotherapy with platinum is the standard treatment for these patients but immunotherapy showed these efficacy …

liver metastasis
gilbert's syndrome
tumor cells
pd-l1
ipilimumab
Clermont Ferrand - CHU
 (1.6 away) Contact site
  • 22 views
  • 25 Jan, 2021
  • +45 other locations
Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)

This is a randomized, double-blind, study that compares pembrolizumab with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with radiotherapy. The primary hypothesis is that pembrolizumab is superior to placebo in increasing …

pembrolizumab
cancer
mk-3475
adjuvant therapy
CH Lyon Sud Hospices Civils de Lyon ( Site 0350)
 (83.6 away) Contact site
  • 69 views
  • 23 Jun, 2021
  • +143 other locations